Current status of amyloid-targeting immunotherapies for Alzheimer's disease

被引：9
|
作者：
Tabor, G. Travis [1 ,2 ,3 ]
Holtzman, David M. [1 ,2 ]
机构：
[1] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63130 USA
[2] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63130 USA
[3] Washington Univ, Sch Med, Med Scientist Training Program, St Louis, MO USA
来源：
SCIENCE TRANSLATIONAL MEDICINE | 2023年 / 15卷 / 721期
关键词：
D O I：
10.1126/scitranslmed.adk9993
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Anti-amyloid antibodies are moving from clinical trials into patients to treat early clinical stages of Alzheimer's disease. Anti-amyloid antibodies are moving from clinical trials into patients to treat early clinical stages of Alzheimer's disease.
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease
    Vander Zanden, Crystal M.
    Chi, Eva Y.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (01) : 68 - 73
  • [12] Advances in amyloid-targeting monoclonal antibodies for Alzheimer's disease: clinical and public health issues
    Salemme, Simone
    Ancidoni, Antonio
    Locuratolo, Nicoletta
    Piscopo, Paola
    Lacorte, Eleonora
    Canevelli, Marco
    Vanacore, Nicola
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, 23 (12) : 1113 - 1129
  • [13] The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
    Joensson, Linus
    Wimo, Anders
    Handels, Ron
    Johansson, Gunilla
    Boada, Merce
    Engelborghs, Sebastiaan
    Froelich, Lutz
    Jessen, Frank
    Kehoe, Patrick Gavin
    Kramberger, Milica
    de Mendon, Alexandre
    Ousset, Pierre Jean
    Scarmeas, Nikolaos
    Visser, Pieter Jelle
    Waldemar, Gunhild
    Winblad, Bengt
    LANCET REGIONAL HEALTH-EUROPE, 2023, 29
  • [14] ⟪Compounded Interest⟫ in Alzheimer's Disease: Do New Amyloid-Targeting Treatments Justify Their Use
    Sampaio, C.
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2023, 10 (03): : 333 - 335
  • [15] «Compounded Interest» in Alzheimer’s Disease: Do New Amyloid-Targeting Treatments Justify Their Use
    Cristina Sampaio
    The Journal of Prevention of Alzheimer's Disease, 2023, 10 : 333 - 335
  • [16] Passive Immunotherapies Targeting Amyloid-β in Alzheimer's Disease: A Quantitative Systems Pharmacology Perspective
    Markovi, Milica
    Milosevic, Jelica
    Wang, Weirong
    Cao, Yanguang
    MOLECULAR PHARMACOLOGY, 2024, 105 (01) : 1 - 13
  • [17] Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
    Plotkin, Steven S.
    Cashman, Neil R.
    NEUROBIOLOGY OF DISEASE, 2020, 144
  • [18] Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer's disease
    Raket, Lars Lau
    Cummings, Jeffrey
    Moscoso, Alexis
    Villain, Nicolas
    Schoell, Michael
    ALZHEIMERS & DEMENTIA, 2024, 20 (09) : 6374 - 6383
  • [19] Current study on diagnosis and treatment of Alzheimer?s disease by targeting amyloid ?-protein
    Hua, Kai -Ye
    Zhao, Wei -Jiang
    FOLIA NEUROPATHOLOGICA, 2023, 61 (01) : 12 - 15
  • [20] Immunotherapies for Alzheimer's disease
    Golde, Todd E.
    Levey, Allan I.
    SCIENCE, 2023, 382 (6676) : 1242 - 1244
12345